Year: 2014
Type: article
Abstract: In 2014 there will be an estimated 235,030 new cases of invasive breast cancer in the United States and breast cancer is the most frequently diagnosed cancer in women with 1 breast cancer diagnosis occurring in every 3 new cancer cases.Even with the advances in breast cancer therapies, such as tamoxifen and trastuzumab, resistance remains a huge problem and the major limitation to overall survival.The research presented in this dissertation attempts to investigate breast cancer signaling pathways, alternative strategies for therapeutic implications and potential mechanisms of resistance to drugs.The second chapter investigates the influence of MAPK signaling on Pol II positioning and activation in association with the immediate early gene, JUNB's proximal promoter and JUNB expression in human breast cancer cell lines.The results of this chapter indicate that constitutive RAS/MAPK signaling enhances the association of Pol II phosphorylated on serine 5 (Pol IIser5p) with the JUNB proximal promoter and treatment with U0126, a MAPK pathway inhibitor, reduces Pol IIser5p association with the JUNB proximal promoter and reduces JUNB expression.This demonstrates that MAPK signaling plays a primary role in the control of JUNB gene expression by promoting the association of Pol IIser5P with the JUNB promoter.
Author: Mellissa Hicks
Institution: The Ohio State University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2626255002